00013 HUTCHMED
WatchlistHUTCHMED News
HUTCHMED: HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
HUTCHMED: Monthly Return of Equity Issuer on Movements in Securities for the month ended October 31, 2023
HUTCHMED: Vesting of awards under the Long Term Incentive Plan
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023
HUTCHMED: Monthly Return of Equity Issuer on Movements in Securities for the month ended September 30, 2023
HUTCHMED: Total Voting Rights
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
HUTCHMED: Director''s Share Dealing
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
HUTCHMED: Monthly Return of Equity Issuer on Movements in Securities for the month ended August 31, 2023
HUTCHMED: Total Voting Rights
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
HUTCHMED: HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
HUTCHMED: Notification letter to non-registered shareholders and request form: Notice of Publication of 2023 Interim Report
HUTCHMED: Notification letter to registered shareholders and request form: Notice of Publication of 2023 Interim Report
HUTCHMED: Letter to new registered shareholders and reply form: Election of Language and Means of Receipt of Corporate Communications
HUTCHMED: 2023 Interim Report
HUTCHMED: Next Day Disclosure Returns
HUTCHMED: Exercise of Share Options by a Director